# Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies

> **NCT02813837** · NA · UNKNOWN · sponsor: **Innovative Cellular Therapeutics Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Leukemia, B-Cell
- Lymphoma, B-Cell

## Interventions

- **BIOLOGICAL:** CD19CART

## Key facts

- **NCT ID:** NCT02813837
- **Lead sponsor:** Innovative Cellular Therapeutics Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-06
- **Primary completion:** 2021-01
- **Final completion:** 2021-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2016-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02813837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02813837, "Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02813837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*